Business Wire

Gilead Sciences Announces Third Quarter 2017 Financial Results

Del

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended September 30, 2017. The financial results that follow represent a year-over-year comparison of the third quarter 2017 to the third quarter 2016. Total revenues were $6.5 billion in 2017 compared to $7.5 billion in 2016. Net income was $2.7 billion or $2.06 per diluted share in 2017 compared to $3.3 billion or $2.49 per diluted share in 2016. Non-GAAP net income, which excludes amounts related to acquisition-related, up-front collaboration, stock-based compensation and other expenses, was $3.0 billion or $2.27 per diluted share in 2017 compared to $3.7 billion or $2.75 per diluted share in 2016.

  Three Months Ended   Nine Months Ended
September 30, September 30,
(In millions, except per share amounts) 2017   2016 2017   2016
Product sales $ 6,402 $ 7,405 $ 19,825 $ 22,737
Royalty, contract and other revenues 110   95   333   333
Total revenues $ 6,512   $ 7,500   $ 20,158   $ 23,070
 
Net income attributable to Gilead $ 2,718 $ 3,330 $ 8,493 $ 10,393
Non-GAAP net income* $ 2,990 $ 3,677 $ 9,311 $ 12,128
 
Diluted earnings per share $ 2.06 $ 2.49 $ 6.44 $ 7.59

Non-GAAP diluted earnings per share*

$ 2.27 $ 2.75 $ 7.06 $ 8.87

* Non-GAAP net income and non-GAAP diluted earnings per share exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.

Product Sales

Total product sales for the third quarter of 2017 were $6.4 billion compared to $7.4 billion for the same period in 2016. Product sales for the third quarter of 2017 were $4.5 billion in the United States, $1.2 billion in Europe and $663 million in other locations. Product sales for the third quarter of 2016 were $5.1 billion in the United States, $1.4 billion in Europe and $931 million in other locations.

Antiviral Product Sales

Antiviral product sales, which include sales of our HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the third quarter of 2017 compared to $6.8 billion for the same period in 2016.

  • HIV and HBV product sales were $3.6 billion compared to $3.5 billion for the same period in 2016. The increase was primarily due to the continued uptake of our tenofovir alafenamide (TAF) based products, Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg).
  • HCV product sales, which consist of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi® (sofosbuvir 400 mg), Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) and Vosevi® (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), were $2.2 billion compared to $3.3 billion for the same period in 2016. The decline was due to lower sales of Harvoni and Sovaldi across all major markets, partially offset by sales of Epclusa, which was approved in the United States and Europe in June and July 2016, respectively, and sales of Vosevi, which was approved in the United States and Europe in July 2017.

Other Product Sales

Other product sales, which include Letairis® (ambrisentan), Ranexa® (ranolazine) and AmBisome® (amphotericin B liposome for injection), were $559 million for the third quarter of 2017 compared to $564 million for the same period in 2016.

Operating Expenses

  Three Months Ended   Nine Months Ended
September 30, September 30,
(In millions) 2017   2016 2017   2016
Research and development expenses (R&D) $ 789 $ 1,141 $ 2,584 $ 3,890
Non-GAAP R&D expenses* $ 745 $ 981 $ 2,446 $ 2,790
 
Selling, general and administrative expenses (SG&A) $ 879 $ 831 $ 2,626 $ 2,406
Non-GAAP SG&A expenses* $ 806 $ 780 $ 2,440 $ 2,256

* Non-GAAP R&D and SG&A expenses exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.

During the third quarter of 2017, compared to the same period in 2016:

  • R&D expenses decreased primarily due to the 2016 impacts of a $200 million milestone expense associated with Nimbus Apollo, Inc. (Nimbus) and a $117 million impairment charge related to in-process R&D.
  • Non-GAAP R&D expenses* decreased primarily due to the 2016 impact of a $200 million milestone expense associated with Nimbus.

Cash, Cash Equivalents and Marketable Securities

As of September 30, 2017, Gilead had $41.4 billion of cash, cash equivalents and marketable securities compared to $36.6 billion as of June 30, 2017. This increase was primarily due to the issuance of $3.0 billion aggregate principal amount of senior unsecured notes in September 2017 to partially fund the purchase of Kite Pharma, Inc. (Kite). The acquisition was completed in October 2017. Cash flow from operating activities was $2.7 billion for the quarter. During the third quarter of 2017, Gilead paid cash dividends of $682 million and utilized $153 million on stock repurchases.

Revised Full Year 2017 Guidance

Gilead revises its full year 2017 guidance, initially provided on February 7, 2017 and revised on July 26, 2017:

(In millions, except percentages and per share amounts)   Initially Provided

February 7, 2017

Reiterated

May 2, 2017

    Updated

July 26, 2017

    Updated
October 26, 2017
Net Product Sales $22,500 - $24,500 $24,000 - $25,500 $24,500 - $25,500
Non-HCV Product Sales $15,000 - $15,500 $15,500 - $16,000 $16,000 - $16,500
HCV Product Sales $7,500 - $9,000 $8,500 - $9,500 $8,500 - $9,000
Non-GAAP*
Product Gross Margin 86% - 88% 86% - 88% 86% - 87%
R&D Expenses $3,100 - $3,400 $3,200 - $3,400 $3,300 - $3,400
SG&A Expenses $3,100 - $3,400 $3,200 - $3,400 $3,300 - $3,400
Effective Tax Rate 25.0% - 28.0% 25.0% - 28.0% 25.0% - 27.0%
Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses $0.84 - $0.91 $0.86 - $0.93 $1.02 - $1.17

* Non-GAAP Product Gross Margin, R&D and SG&A expenses and effective tax rate exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP full year 2017 guidance is provided in the tables on page 9.

Corporate Highlights

  • In August, Gilead and Kite announced that the companies had signed a definitive agreement under which Gilead would acquire all of Kite’s outstanding shares of common stock for $180 per share in cash. The acquisition was completed in early October 2017 for approximately $11.2 billion, excluding $0.7 billion relating to the portion of stock-based compensation attributable to the post combination period.

Product and Pipeline Updates announced by Gilead during the Third Quarter of 2017 include:

Antiviral and Liver Diseases Programs

  • Announced that the China Food and Drug Administration has approved Sovaldi for the treatment of HCV infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine approved in China.
  • Announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Gilead’s new drug application (NDA) for an investigational, fixed-dose combination of bictegravir (50 mg) (BIC), an integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection. Gilead filed the NDA for BIC/FTC/TAF with a priority review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User Fee Act of February 12, 2018.
  • Announced that FDA has approved expanded labeling for Epclusa, the first all-oral, pan-genotypic, once-daily single-tablet regimen for the treatment of adults with HCV infection, to include use in patients co-infected with HIV.
  • Announced that the European Commission and FDA approved Vosevi, a once-daily single-tablet regimen for the treatment of HCV infection in adults with genotypes 1-6. Vosevi is the first and only single-tablet regimen for patients who have previously failed therapy with direct-acting antiviral (DAA) treatments and is the latest regimen in Gilead’s portfolio of sofosbuvir-based HCV DAA treatments.
  • Announced detailed 48-week results from two Phase 3 studies evaluating the efficacy and safety of BIC/FTC/TAF for the treatment of HIV-1 infection in treatment-naïve adults. In the ongoing studies, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing dolutegravir (50 mg). The data was presented in two late-breaker sessions at the 9th International AIDS Conference in Paris. In addition, our marketing authorization application for BIC/FTC/TAF has been fully validated and is now under evaluation by the European Medicines Agency.

Non-GAAP Financial Information

The information presented in this document has been prepared by Gilead in accordance with U.S. generally accepted accounting principles (GAAP), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7, 8 and 9.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead’s management will host a conference call and a simultaneous webcast to discuss results from its third quarter 2017 and a general business update. To access the webcast live via the internet, please connect to the company’s website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 89229005 to access the call.

A replay of the webcast will be archived on the company’s website for one year, and a phone replay will be available approximately two hours following the call through October 28, 2017. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 89229005.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Forward-looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to achieve its anticipated full year 2017 financial results; Gilead’s ability to sustain growth in revenues for its antiviral and other programs; the risk that estimates of patients with HCV or anticipated patient demand may not be accurate; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including YescartaTM, Vosevi, Vemlidy, Epclusa, Descovy, Odefsey and Genvoya; Gilead’s ability to successfully commercialize Yescarta and advance Kite’s product pipeline and any difficulties or unanticipated expenses in connection with integrating the companies; the potential for increased pricing pressure globally and contracting pressure as well as decreased volume and market share from additional competitive HCV launches; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs) and Veterans Administration (VA); continued fluctuations in ADAP and VA purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead’s earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada outside the United States; potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead’s earnings; Gilead’s ability to submit new drug applications and receive regulatory approval for new product candidates in the timelines currently anticipated or at all, including for BIC/FTC/TAF; Gilead’s ability to successfully develop its oncology, inflammation, cardiovascular and respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates; Gilead’s ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead’s future revenues and pre-tax earnings; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission (SEC). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, CAYSTON®, COMPLERA®, DESCOVY®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPSERA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TRUVADA®, TYBOST®, VEMLIDY®, VIREAD®, VITEKTA®, VOLIBRIS®, VOSEVI®, YESCARTATM and ZYDELIG®.

ATRIPLA® is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. LEXISCAN® is a registered trademark of Astellas U.S. LLC. MACUGEN® is a registered trademark of Eyetech, Inc. SUSTIVA® is a registered trademark of Bristol-Myers Squibb Pharma Company. TAMIFLU® is a registered trademark of Hoffmann-La Roche Inc.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

 

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in millions, except per share amounts)

   
Three Months Ended Nine Months Ended
September 30, September 30,
2017   2016 2017   2016
Revenues:
Product sales $ 6,402 $ 7,405 $ 19,825 $ 22,737
Royalty, contract and other revenues 110   95   333   333  
Total revenues 6,512   7,500   20,158   23,070  
Costs and expenses:
Cost of goods sold 1,032 1,129 3,115 3,186
Research and development expenses 789 1,141 2,584 3,890
Selling, general and administrative expenses 879   831   2,626   2,406  
Total costs and expenses 2,700   3,101   8,325   9,482  
Income from operations 3,812 4,399 11,833 13,588
Interest expense (291 ) (242 ) (821 ) (699 )
Other income (expense), net 150   119   391   288  
Income before provision for income taxes 3,671 4,276 11,403 13,177
Provision for income taxes 959   951   2,923   2,788  
Net income 2,712 3,325 8,480 10,389
Net loss attributable to noncontrolling interest (6 ) (5 ) (13 ) (4 )
Net income attributable to Gilead $ 2,718   $ 3,330   $ 8,493   $ 10,393  
 
Net income per share attributable to Gilead common stockholders - basic $ 2.08 $ 2.52 $ 6.50 $ 7.72
Shares used in per share calculation - basic 1,306 1,322 1,307 1,347
Net income per share attributable to Gilead common stockholders - diluted $ 2.06 $ 2.49 $ 6.44 $ 7.59
Shares used in per share calculation - diluted 1,319 1,339 1,319 1,369
Cash dividends declared per share $ 0.52 $ 0.47 $ 1.56 $ 1.37
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in millions, except percentages and per share amounts)

   
Three Months Ended Nine Months Ended
September 30, September 30,
2017   2016 2017   2016
Cost of goods sold reconciliation:
GAAP cost of goods sold $ 1,032 $ 1,129 $ 3,115 $ 3,186
Acquisition-related- amortization of purchased intangibles (209 ) (210 ) (629 ) (630 )
Stock-based compensation expenses (4 ) (4 ) (12 ) (11 )
Other(1) 2   3   (18 ) 9  
Non-GAAP cost of goods sold $ 821   $ 918   $ 2,456   $ 2,554  
 
Product gross margin reconciliation:
GAAP product gross margin 83.9

 %

84.8

 %

84.3

 %

86.0

 %

Acquisition-related- amortization of purchased intangibles 3.3

 %

2.8

 %

3.2

 %

2.8

 %

Other(1)

 %

 %

0.1

 %

 %

Non-GAAP product gross margin(2) 87.2

 %

87.6

 %

87.6

 %

88.8

 %

 
Research and development expenses reconciliation:
GAAP research and development expenses $ 789 $ 1,141 $ 2,584 $ 3,890
Up-front collaboration expenses (5 ) (373 )
Acquisition-related expenses- acquired IPR&D (400 )
Acquisition-related- IPR&D impairment (117 ) (231 )
Stock-based compensation expenses (53 ) (44 ) (142 ) (129 )
Other(1) 9   6   4   33  
Non-GAAP research and development expenses $ 745   $ 981   $ 2,446   $ 2,790  
 
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses $ 879 $ 831 $ 2,626 $ 2,406
Acquisition-related- transaction costs (12 ) (12 )
Stock-based compensation expenses (56 ) (47 ) (150 ) (138 )
Other(1) (5 ) (4 ) (24 ) (12 )
Non-GAAP selling, general and administrative expenses $ 806   $ 780   $ 2,440   $ 2,256  
 
Operating margin reconciliation:
GAAP operating margin 58.5

 %

58.7

 %

58.7

 %

58.9

 %

Up-front collaboration expenses

 %

0.1

 %

 %

1.6

 %

Acquisition-related- amortization of purchased intangibles 3.2

 %

2.8

 %

3.1

 %

2.7

 %

Acquisition-related expenses- acquired IPR&D

 %

 %

 %

1.7

 %

Acquisition-related- IPR&D impairment

 %

1.6

 %

 %

1.0

 %

Acquisition-related- transaction costs 0.2

 %

 %

0.1

 %

 %

Stock-based compensation expenses 1.7

 %

1.3

 %

1.5

 %

1.2

 %

Other(1) (0.1 )% (0.1 )% 0.2

 %

(0.1 )%
Non-GAAP operating margin(2) 63.6

 %

64.3

 %

63.6

 %

67.1

 %

 
Interest expense reconciliation:
GAAP interest expense $ (291 ) $ (242 ) $ (821 ) $ (699 )
Acquisition-related- transaction costs 18     18    
Non-GAAP interest expense $ (273 ) $ (242 ) $ (803 ) $ (699 )
 
Notes:
(1) Amounts related to restructuring, contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts
(2) Amounts may not sum due to rounding
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

(in millions, except percentages and per share amounts)

   
Three Months Ended Nine Months Ended
September 30, September 30,
2017   2016 2017   2016
Effective tax rate reconciliation:
GAAP effective tax rate 26.1

 %

22.2

 %

25.6

 %

21.2

 %

Up-front collaboration expenses

 %

 %

 %

(0.5 )%
Acquisition-related- amortization of purchased intangibles (1.2 )% (0.4 )% (1.2 )% (0.7 )%
Acquisition-related expenses- acquired IPR&D

 %

 %

 %

(0.5 )%
Stock-based compensation expenses(1) 0.8

 %

 %

0.6

 %

 %

Non-GAAP effective tax rate(2) 25.7

 %

21.8

 %

25.0

 %

19.5

 %

 
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead $ 2,718 $ 3,330 $ 8,493 $ 10,393
Up-front collaboration expenses 5 373
Acquisition-related- amortization of purchased intangibles 201 204 605 612
Acquisition-related expenses- acquired IPR&D 400
Acquisition-related- IPR&D impairment 74 173
Acquisition-related- transaction costs 24 24
Stock-based compensation expenses(1) 55 70 161 203
Other(3) (8 ) (6 ) 28   (26 )
Non-GAAP net income attributable to Gilead $ 2,990   $ 3,677   $ 9,311   $ 12,128  
 
Diluted earnings per share reconciliation:
GAAP diluted earnings per share $ 2.06 $ 2.49 $ 6.44 $ 7.59
Up-front collaboration expenses 0.27
Acquisition-related- amortization of purchased intangibles 0.15 0.15 0.46 0.45
Acquisition-related expenses- acquired IPR&D 0.29
Acquisition-related- IPR&D impairment 0.06 0.13
Acquisition-related- transaction costs 0.02 0.02
Stock-based compensation expenses(1) 0.04 0.05 0.12 0.15
Other(3) (0.01 )   0.02   (0.02 )
Non-GAAP diluted earnings per share(2) $ 2.27   $ 2.75   $ 7.06   $ 8.87  
 
Non-GAAP adjustment summary:
Cost of goods sold adjustments $ 211 $ 211 $ 659 $ 632
Research and development expenses adjustments 44 160 138 1,100
Selling, general and administrative expenses adjustments 73 51 186 150
Interest expense adjustments 18     18    
Total non-GAAP adjustments before tax 346 422 1,001 1,882
Income tax effect(1) (74 ) (74 ) (183 ) (151 )
Other(3)   (1 )   4  
Total non-GAAP adjustments after tax $ 272   $ 347   $ 818   $ 1,735  
 
Notes:
(1) Income tax effect related to stock-based compensation expenses for the three and nine months ended September 30, 2017 includes the incremental tax benefit of $27 million and $60 million, respectively, recognized from the adoption of Accounting Standards Update 2016-09 “Improvements to Employee Share-Based Payment Accounting”
(2) Amounts may not sum due to rounding
(3) Amounts related to restructuring, contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2017 FULL YEAR GUIDANCE

(unaudited)

(in millions, except percentages and per share amounts)

     

Initially
Provided
February 7, 2017
Reiterated
May 2, 2017

Updated
July 26, 2017

Updated
October 26, 2017

Projected product gross margin GAAP to non-GAAP reconciliation:
GAAP projected product gross margin 82% - 84% 82% - 84% 82% - 83%
Acquisition-related expenses(1)(3) 4% - 4% 4% - 4% 4% - 4%
Non-GAAP projected product gross margin(2) 86% - 88% 86% - 88% 86% - 87%
 
Projected research and development expenses GAAP to non-GAAP reconciliation:
GAAP projected research and development expenses $3,295 - $3,640 $3,410 - $3,655 $3,535 - $3,685
Stock-based compensation expenses(1)(3) (180) - (195) (195) - (210) (220) - (240)
Acquisition-related expenses(1) / up-front collaboration expenses (15) - (45) (15) - (45) (15) - (45)
Non-GAAP projected research and development expenses $3,100 - $3,400 $3,200 - $3,400 $3,300 - $3,400
 
Projected selling, general and administrative expenses GAAP to non-GAAP reconciliation:
GAAP projected selling, general and administrative expenses $3,305 - $3,615 $3,435 - $3,645 $3,755 - $3,940
Stock-based compensation expenses(1)(3) (205) - (215) (235) - (245) (375) - (435)
Acquisition-related expenses- transaction costs and other(1)

(80) - (105)

Non-GAAP projected selling, general and administrative expenses $3,100 - $3,400 $3,200 - $3,400 $3,300 - $3,400
 
Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses:
Acquisition-related expenses(1) / up-front collaboration expenses $0.62 - $0.67 $0.62 - $0.67 $0.72 - $0.82
Stock-based compensation expenses(1) 0.22 - 0.24 0.24 - 0.26 0.30 - 0.35
Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses $0.84 - $0.91 $0.86 - $0.93 $1.02 - $1.17
 
Notes:
(1) Acquisition-related expenses, including acquisition-related amortization of intangible assets and stock-based compensation expenses, associated with Gilead’s acquisition of Kite are subject to adjustments pending completion of preliminary purchase accounting and valuation
(2) Total stock-based compensation expenses have a less than one percent impact on non-GAAP projected product gross margin
(3) Amounts include preliminary estimates of a range between $188 million and $251 million total stock-based compensation expenses associated with Gilead’s acquisition of Kite
 

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)

   
September 30, December 31,
2017 2016 (1)
 
Cash, cash equivalents and marketable securities $ 41,360 $ 32,380
Accounts receivable, net 4,122 4,514
Inventories 1,144 1,587
Property, plant and equipment, net 3,100 2,865
Intangible assets, net 8,342 8,971
Goodwill 1,172 1,172
Other assets 5,422   5,488
Total assets $ 64,662   $ 56,977
 
Current liabilities $ 9,597 $ 9,218
Long-term liabilities 29,811 28,396
Stockholders’ equity(2) 25,254   19,363
Total liabilities and stockholders’ equity $ 64,662   $ 56,977
 
Notes:
(1) Derived from the audited consolidated financial statements as of December 31, 2016. Certain amounts have been reclassified to conform to current year presentation
(2) As of September 30, 2017, there were 1,307 million shares of common stock issued and outstanding
 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

(in millions)

   
Three Months Ended Nine Months Ended
September 30, September 30,
2017   2016 2017   2016
Antiviral products:
Genvoya – U.S. $ 810 $ 407 $ 2,189 $ 816
Genvoya – Europe 146 46 358 92
Genvoya – Other International 32   8   67   13
988   461   2,614   921
 
Harvoni – U.S. 718 1,084 2,628 3,965
Harvoni – Europe 110 380 583 1,447
Harvoni – Other International 145   396   515   2,029
973   1,860   3,726   7,441
 
Epclusa – U.S. 543 593 2,142 657
Epclusa – Europe 263 40 649 40
Epclusa – Other International 76   7   154   7
882   640   2,945   704
 
Truvada – U.S. 604 573 1,635 1,780
Truvada – Europe 154 217 527 713
Truvada – Other International 53   68   175   205
811   858   2,337   2,698
 
Atripla – U.S. 324 486 974 1,454
Atripla – Europe 79 129 259 412
Atripla – Other International 36   35   133   132
439   650   1,366   1,998
 
Descovy – U.S. 241 65 682 114
Descovy – Europe 65 23 149 35
Descovy – Other International 10     22  
316   88   853   149
 
Odefsey – U.S. 255 95 688 164
Odefsey – Europe 37 10 87 10
Odefsey – Other International 4     6  
296   105   781   174
 
Viread – U.S. 137 155 395 420
Viread – Europe 55 77 202 234
Viread – Other International 82   71   237   208
274   303   834   862
 
Complera / Eviplera – U.S.(1) 91 254 315 675
Complera / Eviplera – Europe 133 143 385 445
Complera / Eviplera – Other International 13   14   44   40
237   411   744   1,160
 
Stribild – U.S.(1) 181 525 632 1,227
Stribild – Europe 40 78 161 243
Stribild – Other International 8   18   38   57
229   621   831   1,527
 
Sovaldi – U.S. 32 363 120 1,783
Sovaldi – Europe 19 184 238 727
Sovaldi – Other International 168   278   489   950
219   825   847   3,460
 
Note:
(1) Amounts for the three and nine months ended September 30, 2016 include a favorable adjustment of rebate reserves of $223 million and $89 million for Stribild and Complera, respectively
 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

(in millions)

   
Three Months Ended Nine Months Ended
September 30, September 30,
2017   2016 2017   2016
Vosevi – U.S. $ 117 $ $ 117 $
Vosevi – Europe 5 5
Vosevi – Other International 1     1  
123     123  
 
Other Antiviral – U.S. 48 14 101 36
Other Antiviral – Europe 7 5 17 18
Other Antiviral – Other International 1     4   2
56   19   122   56
 
Total antiviral products – U.S. 4,101 4,614 12,618 13,091
Total antiviral products – Europe 1,113 1,332 3,620 4,416
Total antiviral products – Other International 629   895   1,885   3,643
5,843   6,841   18,123   21,150
 
Other products:
Letairis 213 215 654 593
Ranexa 164 170 517 467
AmBisome 92 91 276 262
Zydelig 40 39 110 129
Other 50   49   145   136
559   564   1,702   1,587
 
Total product sales $ 6,402   $ 7,405   $ 19,825   $ 22,737

Contact information

Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Sung Lee, 650-524-7792
or
Media
Amy Flood, 650-522-5643

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Indian Detective, Starring Russell Peters, Premieres Tuesday, December 19, 2017 on Netflix Worldwide20.11.2017 16:00Pressemelding

Full release here. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005203/en/ (Photo: Business Wire) Following today’s announcement by Netflix, THE INDIAN DETECTIVE , a four-part comedy-drama series starring international comedy sensation Russell Peters, award-winning actor Anupam Kher (The Big Sick, Silver Linings Playbook), the iconic William Shatner (Star Trek), Christina Cole (Suits, Casino Royale), Hamza Haq (mother!, Bon Cop, Bad Cop 2), Akshay Kumar (Star Wars Ep VIII), Meren Reddy (Madiba, Homeland) and Mishqah Parthiephal (Keeping Up with the Kandasamys, Snake Park), will premiere on December 19, 2017 on Netflix worldwide, following an initial run on CTV Canada in November.

Andersen Global Expands Presence in Italy with New Location in Venice-Mestre, on the Venetian Mainland20.11.2017 14:30Pressemelding

Andersen Global is proud to announce a new presence in Venice-Mestre, on the Venetian mainland in Italy through the expansion of Italian member firm, Andersen Tax & Legal. In addition, the Milan office will relocate at the end of November. The new office in Mestre and new location in Milan have been established to better serve the growing client base in Italy. Andersen Tax & Legal now has six locations in Italy: Milan, Brescia, Rome, Venice, Mestre, and Monza. Andrea De Vecchi, Office Managing Partner of Andersen Tax & Legal in Italy, and Regional Managing Partner in Europe shared, “Our new location in Venice-Mestre and expanded presence in Milan allow us to better serve our clients and continue to build our capabilities within the region. Through this expansion, we are able to reach new markets and also improve the quality of life for our employees.” Venice-Mestre is a sign

NexPlayer HTML5 Player Fully Compatible with Conviva across All Browsers and Devices20.11.2017 14:00Pressemelding

NexStreaming, the provider of NexPlayer SDK, the market leader player SDK for OTT apps, announced today that the NexPlayer HTML5 player is fully compatible with Conviva Video AI Platform. This pre-integrated solution brings great value to video services: from now on, they will be able to enable the highest quality HLS & DASH live streaming across all browsers and devices with NexPlayer, and ensure an outstanding user experience with accurate analytics about the quality of the video experience thanks to Conviva. In this technology integration, NexPlayer HTML5 is fully optimized with Conviva’s QoE analytics. NexPlayer sends information regarding the use of the HTML5 based OTT service, including when the user pauses the video or the video is buffering as well as information about the frame-rate. Conviva measures and analyzes this information so that video service providers and publishers

AGCO’s Innovation Rewarded with Prestigious Awards at Agritechnica 201720.11.2017 14:00Pressemelding

AGCO, Your Agriculture Company, (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment and solutions, achieved remarkable success with 17 major awards at the prestigious Agritechnica 2017 event in Hannover, Germany. As a result of the votes cast by an independent expert committee, AGCO was once again one of the most successful manufacturers at Agritechnica 2017 by way of the number of innovation awards received. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005614/en/ The new Fendt Track Tractor 943 Vario MT won the treasured award "Machine of the Year 2018" in the Category XXL Tractors (Photo: Business Wire) “Winning these significant awards is a testament to our continued commitment to deliver high-tech solutions for farmers feeding the world,” said Martin Richenhagen

Leading Broker ActivTrades Wins Le Fonti Forex Broker of the Year Award for the Second Time20.11.2017 13:30Pressemelding

ActivTrades, one of the world’s leading online Forex Brokers, has won the Le Fonti Forex Broker of the Year Award for the second year running. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005576/en/ ActivTrades was awarded at the Le Fonti Awards (Photo: Business Wire) A UK-regulated firm with offices in Europe and the Middle East, ActivTrades was selected as the winner by the editorial staff of over 120 journalists at Le Fonti, the international and independent media company and research centre. Le Fonti credited the broker for “aiming to maximise its clients’ trading through a unique mix of superior value proposition, diverse product offering and stellar customer service”. Le Fonti’s judges added that ActivTrades offers “some of the tightest spreads in the industry” a

European Commission Extends License for Janssen’s ZYTIGA® Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients20.11.2017 13:30Pressemelding

Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has granted approval to broaden the existing marketing authorisation for ZYTIGA® (abiraterone acetate) plus prednisone / prednisolone to include an earlier stage of metastatic prostate cancer than its current indications. Abiraterone acetate plus prednisone / prednisolone can now be used for the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).1 “Prostate cancer is the most common form of cancer in men throughout Europe and today’s decision helps to fill a critical medical need for these patients. We hope to significantly improve the lives of many men across Europe living with this disease and the approval of this treatment in an earlier stage of prostate cancer helps address this,”

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom